

CLAIMS

1 1. A method for inhibiting the action of TNF- α for treating nerve
2 disorders in a subject by administering a TNF- α inhibitor comprising administering
3 to said subject a therapeutically effective dosage of said TNF- α inhibitor wherein
4 said TNF- α inhibitor is CDP-571 (HUMICADETM), D2E7, or CDP-870.

1 2. The method of claim 1, wherein the subject is a vertebrate.

1 3. The method of claim 2, wherein the vertebrate is a mammal.

1 4. The method of claim 3, wherein the mammal is a human.

1 5. The method of claim 1, wherein said nerve disorder is a spinal
2 disorder.

1 6. The method of claim 1, wherein said nerve disorder is nerve
2 root injury.

1 7. The method of claim 1, wherein said nerve disorder is caused
2 by herniated discs.

1 8. The method of claim 1, wherein said nerve disorder is sciatica.

1 9. The method of claim 1, wherein said nerve disorder involves
2 pain.

1 10. The method of claim 1, wherein said nerve disorder is nucleus
2 pulposus-induced nerve injury.

1 11. The method of claim 1, wherein said nerve disorder is spinal
2 cord compression.

1 12. The method of claim 1, wherein said TNF- α inhibitor is
2 administered systemically or locally.

1 13. The method of claim 1, wherein said TNF- α inhibitor is
2 administered parenterally.

1 14. The method of claim 1, wherein said TNF- α inhibitor is
2 administered intramuscularly, intravenously, subcutaneously, orally, or rectally.

1 15. The method of claim 14, wherein said TNF- α inhibitor is
2 administered intravenously by injection or infusion.

1 16. The method of claim 15, wherein said TNF- α inhibitor is
2 administered orally at a dosage of about 20 mg to about 1,500 mg.

1 17. The method of claim 1, wherein the TNF- α is D2E7 and is
2 administered in a dosage of about 0.1 mg/kg to about 50 mg/kg body weight of said
3 subject.

1 18. The method of claim 1, wherein the TNF- α is CDP-870 and is
2 administered in a dosage of about 1 mg/kg to about 50 mg/kg body weight of said
3 subject.

1 19. A method for inhibiting the action of TNF- α for treating nerve
2 disorders in a subject by administering a TNF- α inhibitor comprising administering
3 to said subject a therapeutically effective dosage of said TNF- α inhibitor wherein
4 said TNF- α inhibitor is a lactoferrin, CT3, ITF-2357, PD-168787, CLX-1100, M-

5 PGA, NCS-700; PMS-601, RDP-58, TNF-484A, PCM-4, CBP-1011, SR-31747,
6 AGT-1, Solimastat, CH-3697, NR58-3.14.3, RIP-3, Sch-23863, or SH-636.

1 20. A pharmaceutical composition for treating nerve disorders in a
2 subject comprising a therapeutically effective amount of a TNF- α inhibitor wherein
3 said TNF- α inhibitor is CDP-571 (HUMICADETM), D2E7, or CDP-870, and a
4 pharmaceutically acceptable carrier, and wherein said pharmaceutical composition
5 inhibits nerve injury when administered to said subject.

1 21. The pharmaceutical composition of claim 20, wherein the
2 subject is a vertebrate.

1 22. The pharmaceutical composition of claim 21, wherein the
2 vertebrate is a mammal.

1 23. The pharmaceutical composition of claim 20, wherein the
2 mammal is a human.

1 24. The pharmaceutical composition of claim 20, wherein said
2 monoclonal antibody is D2E7 in a dosage amount of about 0.1 mg/kg to about 50
3 mg/kg body weight of said subject.

1 25. The pharmaceutical composition of claim 20, wherein said
2 monoclonal antibody CDP-870 in an amount of about 1.0 mg/kg to about 50 mg/kg
3 body weight of said subject.

1 26. The pharmaceutical composition of claim 20, wherein said
2 nerve disorder is selected from the group consisting of a spinal disorder, a nerve
3 root injury, a nerve disorder caused by herniated discs, a nerve disorder involving
4 pain, a nucleus pulposus-induced nerve injury, a spinal cord compression, and

5 sciatica.

1 27. The pharmaceutical composition of claim 20, wherein said
2 pharmaceutical composition is formulated for intravenous, intramuscular, oral,
3 rectal, or subcutaneous administration.

1 28. The pharmaceutical composition of claim 20, wherein said
2 pharmaceutical composition is formulated for parenteral administration.

1 29. A pharmaceutical composition for treating nerve disorders in a
2 subject comprising a therapeutically effective amount of a TNF- α inhibitor wherein
3 said TNF- α inhibitor is a lactoferrin, CT3, ITF-2357, PD-168787, CLX-1100, M-
4 PGA, NCS-700; PMS-601, RDP-58, TNF-484A, PCM-4, CBP-1011, SR-31747,
5 AGT-1, Solimastat, CH-3697, NR58-3.14.3, RIP-3, Sch-23863, or SH-636, and a
6 pharmaceutically acceptable carrier, and wherein said pharmaceutical composition
7 inhibits nerve injury when administered to said subject.